Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Iovance Biotherapeutics (IOVA) Accumulated Depreciation & Amortization: 2013-2025

Historic Accumulated Depreciation & Amortization for Iovance Biotherapeutics (IOVA) over the last 3 years, with Sep 2025 value amounting to $45.3 million.

  • Iovance Biotherapeutics' Accumulated Depreciation & Amortization was N/A to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.2 million, marking a year-over-year change of. This contributed to the annual value of $36.0 million for FY2024, which is 29.04% up from last year.
  • Iovance Biotherapeutics' Accumulated Depreciation & Amortization amounted to $45.3 million in Q3 2025, which was up 7.65% from $42.1 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Accumulated Depreciation & Amortization ranged from a high of $45.3 million in Q3 2025 and a low of $19.4 million during Q1 2023.
  • Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $30.9 million (2024), whereas its average is $32.0 million.
  • Data for Iovance Biotherapeutics' Accumulated Depreciation & Amortization shows a peak YoY spiked of 59.45% (in 2024) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $27.9 million in 2023, then grew by 29.04% to $36.0 million in 2024, then grew by 25.48% to $45.3 million in 2025.
  • Its Accumulated Depreciation & Amortization was $45.3 million in Q3 2025, compared to $42.1 million in Q2 2025 and $38.8 million in Q1 2025.